CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Enhanced Validation Data Anti-EGFRvIII Recombinant Antibody

  Select the right antibody clone by exploring enhanced validation data for top recombinant antibody clones that offer comprehensive specificity and sensitivity insights tailored to your project's unique requirements.

• Drug Development Plan Explained: DPP Templates And Examples

  Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.

• CDMO Selection For Small Biotech: Amit Jain On Avoiding Costly Transfers

  Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.

• Matrigel Dome Assay And Drug Screening Of Colorectal Cancer Organoids

  Using CRC organoids and bioprinting, explore the automation of dome assays to evaluate drug responses and delve into the insights from image-based end-point assays on the efficacy of anti-cancer treatments.

• Overcome Patient-Level Access Barriers For New Medicine

  Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.

• Microbial Recovery And Flow Performance With Membranes

  Compare membrane materials and pore sizes to assess their impact on flow rate and microbial recovery. See how fast filtration and ≥90% organism recovery offer guidance for selecting reliable membranes.

• Decoding AAV: Navigating Critical Quality Attributes And Their Analytics

  For groundbreaking genetic treatments, stringent quality control is non-negotiable. This exploration delves into defining essential attributes and the analytical tools that safeguard their consistent production.

• Standardizing Cryopreservation For Cell Therapy Supply Chains

  Explore how a standardized cryopreservation process is transforming leukapheresis handling by reducing risk and improving quality across the cell therapy supply chain.

• Risk Assessment Services Align With FDA Guidance For Gene-Edited Human Gene Therapy Products

  Navigate the FDA's gene therapy guidelines with advanced risk assessment strategies. Optimize gene editing and ensure regulatory alignment for safer, more effective therapies.

• A Comparison To Traditional Clone Screening Platforms

  See how 46 CHO clones performed across automated, deep-well, and microbioreactor fed-batch cultures, using cell density, viability, and IgG concentration to evaluate clone performance.